DANTE-LABS
10.10.2019 12:13:07 CEST | Business Wire | Press release
Dante Labs announced today the official launch of its premium 2-week turnaround time for its whole genome sequencing tests. On average, genetics labs in Europe, Asia and the United States offer turnaround times between six to ten weeks, and just for the raw data. Dante Labs offers reports and raw data within two weeks from receiving the sample back.
The new service is possible thanks to the new Illumina-backed, high-throughput, automated sequencing centre that Dante Labs built in Italy, fully dedicated to the classical Whole Genome and the WholeGenomeZ™ sequencing tests.
“It is a huge difference to have our own sequencing centre.” Dante Labs CEO Andrea Riposati says. “We thought we could offer best in class service by externalizing the sequencing to third party labs. Through our initial model, thousands of people received their full whole genome results at affordable prices, receiving a full picture of their DNA for the first time in their life, often after years of guessing and after life-long undiagnosed odysseys. However, in the last twelve months about 20% of our users experienced delays – in some cases significant ones – because of delays from third party labs. Now, we can go from being criticized as ‘too slow’ to providing first-class sequencing speed matched with the first-class quality of our sequencing lab. If someone needs an urgent whole genome sequencing, we are the go-to-company.”
In order to ensure everyone received results on time and is also fully aware of the status of its samples, Dante Labs made significant investments in the last four months:
- Dante Labs built its own high-throughput sequencing center in L’Aquila, Italy, a 900-square meter GDPR-compliant, certified facility;
- Dante Labs fully internalized its non-US logistics in Italy and selected a new, best-in-class fulfilment partner in North America;
- Dante Labs developed a clearer messaging system to alert individuals about the status of their samples, including visual widgets and smart automated emails, personalized for family members who registered multiple kits and ordered multiple reports;
The price of the Premium Whole Genome is €899 (or $949) for the fast turnaround time vs. €599 (or $649) for the standard turnaround time. The price for the Super Premium WholeGenomeZ is €1399 (or $1499) for the fast turnaround time, and €899 (or $999) for the standard turnaround time.
These prices are still way below what individuals are forced to pay by offline labs across Europe, North America, South America, Oceania and Asia.
About Dante Labs
Dante Labs is global genetic testing and data analysis company specialized in whole genome sequencing and interpretation. To learn more or to purchase a Dante Labs whole genome sequencing test, visit www.dantelabs.com and follow @DanteLabs , or visit our YouTube Channel .
View source version on businesswire.com: https://www.businesswire.com/news/home/20191010005388/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Corpay Cross-Border Named the Official FX Supplier of Toulouse Football Club23.4.2026 14:30:00 CEST | Press release
Providing access to currency risk management and cross-border payments solutions Corpay, Inc.*, (NYSE: CPAY) a global leader in corporate payments, is pleased to announce that Corpay’s Cross-Border business has entered into an agreement with Toulouse Football Club to become their Official Foreign Exchange (FX) Supplier. A partnership brought together by SPORTFIVE, an international sports marketing agency. Through this partnership, Corpay Cross-Border will deliver comprehensive FX risk management solutions to support Toulouse Football Club’s operations. In addition, its award-winning platform will enable the club to manage global payments seamlessly through a single point of access. “Corpay Cross-Border is proud to be named the Official FX Supplier of Toulouse Football Club,” said Brad Loder, Chief Marketing Officer, Corpay Cross-Border Solutions. “This partnership reinforces Corpay’s position as a leading provider of corporate payments and currency risk management solutions within prof
Philip Morris International Expands its Partnership with Ducati Corse as Decades-Long Partnership Races Forward with Purpose23.4.2026 14:00:00 CEST | Press release
ZYN branding to be present at select MotoGP races in the 2026 season and beyond Philip Morris International1 (NYSE: PM) today announced an expanded partnership with Ducati Corse for the 2026 season and beyond. This next chapter introduces a major development: the ZYN brand of nicotine pouches—the number one nicotine pouch brand globally2—will feature on Ducati Corse MotoGP liveries at select races throughout the seasons. Just as Ducati pushes the limits of performance, ZYN represents PMI’s commitment to delivering innovation, offering a product that delivers exceptional quality while being thoughtfully designed. This partnership allows ZYN to connect with adult consumers in a space they’re passionate about—and to do so in a way that’s authentic, respectful, and dynamic. Philip Morris International’s relationship with Ducati Corse began in 2003—the year Ducati arrived in MotoGP—ushering in a bold new era of ambition. Since then, the collaboration has evolved alongside both organizations
Vitrealab and poLight ASA Partner to Tackle Coherence Artifacts in Laser-LCoS AR Displays23.4.2026 14:00:00 CEST | Press release
Vitrealab GmbH and poLight ASA (OSE: PLT) today announced a collaboration to advance laser illumination architectures for LCoS-based augmented reality (AR) displays, with a focus on mitigating coherence-related image artifacts while preserving system efficiency and compactness. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260423345474/en/ Vitrealab GmbH and poLight ASA (OSE: PLT) today announced a collaboration to advance laser illumination architectures for LCoS-based augmented reality (AR) displays, with a focus on mitigating coherence-related image artifacts while preserving system efficiency and compactness. Vitrealab’s Quantum Light Chip combined with poLight's TWedge® wobulation technology helps create a higher performing and more manufacturable AR system. Laser-based illumination offers clear system-level advantages for LCoS based AR light engines, including high optical efficiency due to intrinsic polarization, imp
GE HealthCare Announces First Patient Dosed in Phase 2/3 LUMINA Trial for Manganese-Based MRI Contrast Agent Under FDA Fast Track Designation, Further Advancing Its Innovation Pipeline of Novel Imaging Agents23.4.2026 13:29:00 CEST | Press release
Mangaciclanol, if approved, could transform contrast-enhanced MR imaging by offering an alternative to - or even replacing - gadolinium-based MRI agentsA manganese-based MRI contrast agent could address concerns with gadolinium-based contrast agents around retention in the body, security of supply, and the environment, with mangaciclanol’s clinical development under FDA Fast Track designationThe program demonstrates GE HealthCare’s commitment to advancing novel imaging agents to address unmet patient needs GE HealthCare (Nasdaq: GEHC) today announced the first patient has been dosed in the international, multi-center Phase 2/3 LUMINA clinical trial of its manganese-based magnetic resonance imaging (MRI) contrast agent, mangaciclanol, at Mayo Clinic in Rochester, Minnesota. Mangaciclanol, if approved, could offer an alternative to – or even replace – gadolinium-based MRI contrast agents, the current standard of care. The investigational agent has been granted Fast Track designation by t
Croma Pharma Launches AI-Driven Tech Venture to Revolutionize Aesthetic Medicine via Clinicore Platform23.4.2026 13:13:00 CEST | Press release
New structure to drive AI-powered innovation and international expansion Croma Pharma has launched a strategic joint venture to accelerate the development of Clinicore, its premium digital solution for aesthetic practices. This dedicated entity will focus on scaling the next generation of the platform while ensuring full continuity for existing users. Clinicore: Elevating Practice Excellence through AI Clinicore is a specialized SaaS (Software as a Service) solution designed to optimize the daily operations of aesthetic clinics. By automating patient management, scheduling, and administrative workflows, it enables healthcare professionals to focus entirely on patient care. A core element of the new strategy is a strong focus on Artificial Intelligence. Clinicore is evolving into a smart assistant, utilizing AI-driven features for automated treatment documentation, intelligent onboarding tools, and advanced process automation. This ensures that clinics can operate at maximum efficiency
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom